Pelotonia Institute for Immuno-Oncology

Congrats to #PIIO member Dr. @NandiniAacharya and team on this exciting new study! They show how #tumor_immunogenicity shapes CNS immune niches, with the meninges sustaining stem‑like & memory CD8⁺ T cells in GBM. #Glioblastoma #Immunology pubmed.ncbi.nlm.nih.gov/41826987/

Check out this recent commentary in @ImmunityCP by Drs. Yi-Ju Chou and @DrSTANtheMAN on the Ji et al. Immunity paper! FLI1 blocks UPR survival programs under nutrient stress, limiting #NKcell persistence in #tumors. pubmed.ncbi.nlm.nih.gov/41812640/

📝New publication from @dwightowenmd, @dspakowicz & colleagues in Cancer Immunology, Immunotherapy: Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures doi.org/10.1007/s00262…

We are hiring! go.osu.edu/medonccareers @OSUCCC_James @OhioStateMedOnc

🎉 New Publication Alert! 🎉 Breakthrough research led by #PIIO member Dr. Steve Oghumu uncovers how #sex_based_immune_differences shape tumor progression in head & neck squamous cell carcinoma. 🔬🔥 📖 Read more: pubmed.ncbi.nlm.nih.gov/41818928/

🎉 Big Congratulations to Yi Wang (@Zihai Li Lab)! 🎉 Join us in celebrating Yi’s PhD Dissertation Defense at the @Pelotonia Institute for Immuno‑Oncology! 🧬🔥 Her groundbreaking work uncovering how #proteotoxic_stress drives #T_cell_exhaustion — including the discovery of the Tex‑PSR pathway published in @Nature — is pushing immuno‑oncology forward in a big way. 🚀 📅 Monday, March 23, 2026 🕑 2:00–3:00 PM | 130 EAIC 🥂 Reception at 4:30 PM | PRC 3rd Floor Lobby Let’s cheer on Yi as she defends her incredible research! 👏🔬 #Immunology #PhDDefense #OSU #CancerResearch #FutureLeader

Join us March 18, 2026 • 12–1 PM at 130 EAIC for the @OhioStatePIIO @OhioStateMedOnc Distinguished Professor Seminar featuring Dr. Hassane Zarour of UPMC Hillman Cancer Center. 🧬 “Multiple Paths to Potent Anti‑Melanoma Immunotherapy: Context Matters” Don’t miss this deep dive into cutting‑edge #melanoma #immunotherapy and #Tcell biology.

Thank you for taking the time to tour the #PIIO! We’re excited about the momentum ahead and the opportunities to deepen our partnership as we drive breakthroughs in #CancerImmunology

The @Zihai Li Research Group at the #PIIO is hiring an #ImmunoOncology Research Senior Writer. Work with world-class scientists and help move discoveries from bench → bedside. 👉 Apply: go.osu.edu/io_science_wri… #Hiring #ScienceWriter #Immunotherapy #CancerResearch #SciComm

W. Kimryn Rathmell, MD, PhD, CEO of @OSUCCC_James, is the new director of The Ohio State University Comprehensive Cancer Center. Raphael E. Pollock, MD, PhD, now serves as director emeritus. Read more in the March #AACIUpdate: bit.ly/4ssjyNY

Predicting #CARNK activity is challenging, but a research group led by Drs. Meisam Naeimi Kararoudi, Dean Lee and Jayajit Das present a new in silico experimental framework that predicts in‑vitro & in‑vivo cytotoxicity with high accuracy (@PNASNews). A step forward for #Immunotherapy and #MultiscaleModeling. pmc.ncbi.nlm.nih.gov/articles/PMC12…

🎥 “Inside the body, cancer divides. But inside The @OSUCCC_James, we unite!” Work being done at the @Pelotonia Research Center is truly transforming cancer research and treatment. While #cancer hides, we hunt! 👇 🔗 youtu.be/--rHuvGOXCI?si…

Congrats Dr Kendra and team for this impressive publication! @OSUCCC_James

🎉 Congratulations to PIIO ESAB member Dr. @MiriamMerad! Thrilled to see @SinaiImmunol launch ORIGIN, a groundbreaking new collaboration with the Uniformed Services University aimed at predicting and preventing disease before symptoms even appear. A major step forward for immune‑driven precision health. 🔗 mountsinai.org/about/newsroom… #Immunology #PrecisionMedicine #EarlyDetection #DiseasePrevention #PIIO #ImmunoOncology #MedicalResearch

🚨 We’re Hiring! The Center for #InnateImmunity & #Inflammation (CIII) (@OhioStateSurg, @OhioStatePIIO) is seeking talented scientists in #innate_immunology, #immuno_oncology, #dendritic_cell_biology, #CNSinnate_immunity, & #translational research to improve #cancer outcomes. Join us in advancing transformative #cancer_immunology. APPLY NOW: go.osu.edu/ciii_faculty

📢 Join us for our next #PIIO Research-in-Progress Seminar! "Pregnancy Provides a Blueprint for #NKCell Heterogeneity in Human #EndometrialCancer" 🗓️ Friday, February 6, 2026 ⏰ 10:00 AM 📍 EAIC 130 👩‍🔬 Presenter: Caprice Eisele, PhD Candidate, BSGP 🧬 Mentor: Aharon Freud, MD, PhD Don’t miss this exploration of #NKcell diversity and its implications for "!

📢 Join us for our next #PIIO Research-in-Progress Seminar! "#scRNA_Sequencing Reveals #Natural_Killer_Cell Diversity in #Human_Endometrial_Cancer" 🗓️ Friday, February 6, 2026 ⏰ 10:00 AM 📍 EAIC 130 👩‍🔬 Presenter: Caprice Eisele, PhD Candidate, BSGP 🧬 Mentor: Aharon Freud, MD, PhD Don’t miss this exploration of #NKcell diversity and its implications for #ImmunoOncology!

On #WorldCancerDay, we’re joining our CEO, W. @KimrynRathmell, MD, PhD, in celebrating progress while affirming our commitment to the creation of a cancer-free world through research innovation and partnerships with patients, families, colleagues and our community.

Thank you, Dr. AJ Robert McGray (@RoswellPark) for an outstanding #Immunology, #Infection & #ImmunoOncology (i3) Seminar Series talk! “BiTE‑secreting #Tcells for #adoptive_Tcell_therapy in #ovarian_cancer: Exploring rational combination approaches." #CME‑credited @OhioState #MIIProud @OhioStateRheum @OhioStatePIIO

📝New publication from Dr. Kari Kendra & colleagues in @NatureCancer : Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial doi.org/10.1038/s43018…